The effect of taking ibrutinib for chronic lymphocytic leukemia varies from person to person, there is no specific data, it is recommended to take the drug under the guidance of a doctor and regular review.
Ibrutinib is mainly used for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, or sleeve cell lymphoma that has received at least one type of previous treatment. There are no clear data on the time to onset of action after taking ibrutinib for chronic lymphocytic leukemia.
Adverse reactions such as neutropenia, anemia, nausea, rash, skeletal muscle pain, fever, and diarrhea may occur with ibrutinib. Pregnant and lactating women need to use the drug with caution, and the drug is contraindicated for those who are allergic to ibrutinib. If there is any discomfort promptly stop the drug and go to the hospital for examination.